16,570 reports of this reaction
2.1% of all DUPILUMAB reports
#11 most reported adverse reaction
ARTHRALGIA is the #11 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 16,570 FDA adverse event reports linking DUPILUMAB to ARTHRALGIA. This represents approximately 2.1% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 16,570 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.1% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience arthralgia while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.